Use of EtCO2 as a PaCO2 Predictor Under Non Invasive Ventilation (NIV) in Cases of Acute Hypercapnic Respiratory Failure

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Prof. Philippe Jolliet, University of Lausanne Hospitals

ClinicalTrials.gov Identifier:

NCT01489150

First received: December 2, 2011

Last updated: May 15, 2013

Last verified: May 2013

History of Changes

Purpose

In patients treated by Non invasive ventilation (NIV) due to acute hypercapnic respiratory failure, the interest of using the End-tidal Co2 measurement device "Capnostream" to evaluate PaCo2 and PaCo2 variations over time will be evaluated. Measurements will be done under normal expiration and under prolonged active and passive expiration maneuvers.

Condition
Hypercapnic Respiratory Failure


Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Use of EtCO2 and Prolonged Expiratory Maneuvers as a PaCO2 Predictor in Cases of Acute Hypercapnic Respiratory Failure

Resource links provided by NLM:

MedlinePlus related topics: Respiratory Failure

U.S. FDA Resources

Further study details as provided by University of Lausanne Hospitals:

Primary Outcome Measures:

Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration [ Time Frame: Sixty minutes ] [ Designated as safety issue: No ]
Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration


Enrollment:	11
Study Start Date:	December 2011
Study Completion Date:	December 2012
Primary Completion Date:	April 2012 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Intensive care unit patients equipped with arterial line requiring non invasive ventilation because of acute hypercapnic respiratory failure

Criteria

Inclusion Criteria:

ICU patient equipped with arterial line
NIV requirement
Hypercapnia: PaCO2 > 45mmhg

Exclusion Criteria:

Severe hemodynamic instability
Severe psychiatric disorders
nasal lesions
denied consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489150

Locations


Switzerland
Intensive care and burn unit, University Hospital of Lausanne
Lausanne, Switzerland, 1011

Sponsors and Collaborators

University of Lausanne Hospitals

Investigators


Principal Investigator:	Philippe Jolliet, Professor	University of Lausanne Hospitals

More Information


Responsible Party:	Prof. Philippe Jolliet, Principal investigator, University of Lausanne Hospitals
ClinicalTrials.gov Identifier:	NCT01489150 History of Changes
Other Study ID Numbers:	EtCO2-NIV
Study First Received:	December 2, 2011
Last Updated:	May 15, 2013
Health Authority:	Switzerland: Laws and standards

Keywords provided by University of Lausanne Hospitals:


Acute respiratory failure Hypercapnia Non invasive ventilation End-tidal CO2

Additional relevant MeSH terms:


Respiratory Insufficiency Hypercapnia Respiration Disorders	Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms

ClinicalTrials.gov processed this record on September 26, 2016

To Top